Premium Nahrungsergänzungsmittel | artgerecht

CTLA-4 Blockade: Immune Checkpoint Therapy

CTLA-4 blockade is a form of immune checkpoint therapy that enhances the immune system to fight cancer cells. It is primarily used in oncology.

Regular tips about health Regular tips about health

Things worth knowing about "CTLA-4 Blockade"

CTLA-4 blockade is a form of immune checkpoint therapy that enhances the immune system to fight cancer cells. It is primarily used in oncology.

What is CTLA-4 Blockade?

CTLA-4 blockade is an immunotherapeutic strategy that targets and inhibits the molecule CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein 4). CTLA-4 is an immune checkpoint – a regulatory mechanism that normally suppresses the activity of T-lymphocytes (white blood cells). By blocking this protein, the immune response against tumor cells is significantly enhanced.

Mechanism of Action

T-cells are central components of the body's immune defense. Their activation requires two signals: first, the recognition of an antigen, and second, a co-stimulatory signal triggered by the binding of CD28 to B7-1 or B7-2 molecules on antigen-presenting cells.

CTLA-4 competes with CD28 for the same binding partners (B7-1/B7-2) but has a higher binding affinity. When CTLA-4 binds, T-cell activation is suppressed – a mechanism that under normal conditions prevents excessive immune reactions.

Tumor cells can exploit this mechanism to evade immune recognition. CTLA-4-blocking antibodies (e.g., Ipilimumab) prevent this inhibition, thereby promoting stronger T-cell activation against the tumor.

Clinical Applications

CTLA-4 blockade is primarily used in oncological treatment. Approved indications include:

Malignant melanoma: Ipilimumab was the first approved CTLA-4 inhibitor.
Non-small cell lung cancer (NSCLC): in combination with other checkpoint inhibitors.
Renal cell carcinoma: in combination with PD-1 inhibitors such as Nivolumab.
Colorectal cancer with microsatellite instability.
Additional tumor entities within clinical trials.

Combination with Other Immunotherapies

CTLA-4 blockade is frequently combined with PD-1 or PD-L1 inhibitors to achieve a synergistic effect. While CTLA-4 inhibitors act early in the T-cell priming phase, PD-1/PD-L1 inhibitors primarily affect the effector T-cell phase. Combination regimens can significantly improve response rates, but also increase the risk of side effects.

Side Effects

Since CTLA-4 blockade broadly stimulates the immune system, immune-related adverse events (irAEs) can occur:

Skin: rash, pruritus, vitiligo
Gastrointestinal tract: diarrhea, colitis
Liver: hepatitis (elevated liver enzymes)
Endocrine system: hypophysitis, thyroiditis, adrenalitis
Lungs: pneumonitis
Rarely, life-threatening immune reactions

Management of these side effects typically involves corticosteroids or other immunosuppressive agents. In severe cases, treatment must be paused or permanently discontinued.

Dosage and Administration

CTLA-4 inhibitors are administered as intravenous infusions. Ipilimumab is typically given every three weeks, with a standard dose of 3 mg/kg body weight in melanoma. In combination regimens, lower doses (e.g., 1 mg/kg) may be used. The exact dosage always depends on the specific treatment protocol and the disease being treated.

Significance in Modern Oncology

The development of CTLA-4 blockade is considered a milestone in cancer therapy. The discovery of this principle was awarded the Nobel Prize in Physiology or Medicine in 2018 (James P. Allison and Tasuku Honjo). It opened a new era of immuno-oncology and laid the foundation for numerous subsequent checkpoint therapies.

References

Allison JP. - Checkpoints. - Cell. 2015;162(6):1244-1245. (PubMed)
Wolchok JD et al. - Nivolumab plus Ipilimumab in Advanced Melanoma. - N Engl J Med. 2013;369(2):122-133.
European Medicines Agency (EMA) - Yervoy (Ipilimumab) - Product Information. - ema.europa.eu (2024).

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.